Race Oncology Discloses New Strategy for Bisantrene

  • Nov 14, 2019 AEDT
  • Team Kalkine

Race Oncology Limited (ASX: RAC), a specialty pharmaceutical company, has disclosed its new “5 Path” clinical strategy for Bisantrene, its cancer drug. The strategy defines five new paths for the clinical development of the drug, that greatly expands its addressable market.

  • These five strategies will reduce clinical development risk and target cancers beyond Acute Myeloid Leukaemia (AML);
  • The company will continue to focus on the use of Bisantrene in treating AML but will pursue to introduce the drug earlier in the treatment pathway.

At AEST 12:59 PM, the stock was trading at $0.130 per share, no change from its previous close.


All pictures are copyright to their respective owner(s).Kalkinemedia.com does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK